Cargando…

SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses

In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorino, Sirio, Carusi, Andrea, Hong, Wandong, Cernuschi, Paolo, Gallo, Claudio Giuseppe, Ferrara, Emanuele, Maloberti, Thais, Visani, Michela, Lari, Federico, de Biase, Dario, Zippi, Maddalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AIMS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834075/
https://www.ncbi.nlm.nih.gov/pubmed/36694588
http://dx.doi.org/10.3934/microbiol.2022029
_version_ 1784868380674621440
author Fiorino, Sirio
Carusi, Andrea
Hong, Wandong
Cernuschi, Paolo
Gallo, Claudio Giuseppe
Ferrara, Emanuele
Maloberti, Thais
Visani, Michela
Lari, Federico
de Biase, Dario
Zippi, Maddalena
author_facet Fiorino, Sirio
Carusi, Andrea
Hong, Wandong
Cernuschi, Paolo
Gallo, Claudio Giuseppe
Ferrara, Emanuele
Maloberti, Thais
Visani, Michela
Lari, Federico
de Biase, Dario
Zippi, Maddalena
author_sort Fiorino, Sirio
collection PubMed
description In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination.
format Online
Article
Text
id pubmed-9834075
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AIMS Press
record_format MEDLINE/PubMed
spelling pubmed-98340752023-01-23 SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses Fiorino, Sirio Carusi, Andrea Hong, Wandong Cernuschi, Paolo Gallo, Claudio Giuseppe Ferrara, Emanuele Maloberti, Thais Visani, Michela Lari, Federico de Biase, Dario Zippi, Maddalena AIMS Microbiol Overview In recent weeks, the rate of SARS-CoV-2 infections has been progressively increasing all over the globe, even in countries where vaccination programs have been strongly implemented. In these regions in 2021, a reduction in the number of hospitalizations and deaths compared to 2020 was observed. This decrease is certainly associated with the introduction of vaccination measures. The process of the development of effective vaccines represents an important challenge. Overall, the breakthrough infections occurring in vaccinated subjects are in most cases less severe than those observed in unvaccinated individuals. This review examines the factors affecting the immunogenicity of vaccines against SARS-CoV-2 and the possible role of nutrients in modulating the response of distinct immune cells to the vaccination. AIMS Press 2022-11-16 /pmc/articles/PMC9834075/ /pubmed/36694588 http://dx.doi.org/10.3934/microbiol.2022029 Text en © 2022 the Author(s), licensee AIMS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) )
spellingShingle Overview
Fiorino, Sirio
Carusi, Andrea
Hong, Wandong
Cernuschi, Paolo
Gallo, Claudio Giuseppe
Ferrara, Emanuele
Maloberti, Thais
Visani, Michela
Lari, Federico
de Biase, Dario
Zippi, Maddalena
SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title_full SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title_fullStr SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title_full_unstemmed SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title_short SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
title_sort sars-cov-2 vaccines: what we know, what we can do to improve them and what we could learn from other well-known viruses
topic Overview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834075/
https://www.ncbi.nlm.nih.gov/pubmed/36694588
http://dx.doi.org/10.3934/microbiol.2022029
work_keys_str_mv AT fiorinosirio sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT carusiandrea sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT hongwandong sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT cernuschipaolo sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT galloclaudiogiuseppe sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT ferraraemanuele sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT malobertithais sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT visanimichela sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT larifederico sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT debiasedario sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses
AT zippimaddalena sarscov2vaccineswhatweknowwhatwecandotoimprovethemandwhatwecouldlearnfromotherwellknownviruses